CRISPR Reagents

AKT1 Gene Knockout Kit (Human)

Knockout any human or mouse protein-coding gene with XDel technology.

Bulk Upload
Need a quote? Add to cart and download one instantly at checkout — to reference on a purchase order, submit for budget approval, or keep for your records. No need to contact sales.

ENSG00000142208
This gene encodes one of the three members of the human AKT serine-threonine protein kinase family which are often referred to as protein kinase B alpha, beta, and gamma. These highly similar AKT proteins all have an N-terminal pleckstrin homology domain, a serine/threonine-specific kinase domain and a C-terminal regulatory domain. These proteins are phosphorylated by phosphoinositide 3-kinase (PI3K). AKT/PI3K forms a key component of many signalling pathways that involve the binding of membrane-bound ligands such as receptor tyrosine kinases, G-protein coupled receptors, and integrin-linked kinase. These AKT proteins therefore regulate a wide variety of cellular functions including cell proliferation, survival, metabolism, and angiogenesis in both normal and malignant cells. AKT proteins are recruited to the cell membrane by phosphatidylinositol 3,4,5-trisphosphate (PIP3) after phosphorylation of phosphatidylinositol 4,5-bisphosphate (PIP2) by PI3K. Subsequent phosphorylation of both threonine residue 308 and serine residue 473 is required for full activation of the AKT1 protein encoded by this gene. Phosphorylation of additional residues also occurs, for example, in response to insulin growth factor-1 and epidermal growth factor. Protein phosphatases act as negative regulators of AKT proteins by dephosphorylating AKT or PIP3. The PI3K/AKT signalling pathway is crucial for tumor cell survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating AKT1 which then phosphorylates and inactivates components of the apoptotic machinery. AKT proteins also participate in the mammalian target of rapamycin (mTOR) signalling pathway which controls the assembly of the eukaryotic translation initiation factor 4F (eIF4E) complex and this pathway, in addition to responding to extracellular signals from growth factors and cytokines, is disregulated in many cancers. Mutations in this gene are associated with multiple types of cancer and excessive tissue growth including Proteus syndrome and Cowden syndrome 6, and breast, colorectal, and ovarian cancers. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Jul 2020]
Molecular Function20
Biological Process104
Cellular Component17

Common questions about the AKT1 knockout kit

How many guides does the AKT1 knockout kit use?
The kit's XDel design targets AKT1 with 3 guides, and the earliest cut is in exon 4 of its canonical transcript.
Which AKT1 transcripts does the knockout cut?
The XDel guides cut 112 AKT1 transcripts, including the canonical transcript ENST00000649815. They cut all 51 of its CCDS protein-coding transcripts.
Do the AKT1 guides cut other genes?
No. Our design analysis predicts no off-target potential in any other gene for these guides.
Gene Knockout Kits Provide Superior Editing Efficiency in iPSC, Immortalized, and Primary Cells and Consistent Protein Depletion Using the XDel Design
XDel is a cutting-edge CRISPR knockout technology designed to remove the guesswork from gene editing. By leveraging an innovative guide RNA design strategy, XDel delivers highly efficient, consistent, and reproducible gene knockouts—empowering researchers to accelerate their discoveries with confidence.